A new risk model based on a 11-m$^6$A-related IncRNA signature for predicting prognosis and monitoring immunotherapy for gastric cancer

Liangliang Lei$^1$, Nannan Li$^2$, Pengfei Yuan$^1$* and Dechun Liu$^1$*

Abstract

Objective: $N^6$-methyladenosine (m$^6$A) mRNA modification triggers malignant behaviors of tumor cells and thereby drives malignant progression in gastric cancer (GC). However, data regarding the prognostic values of m$^6$A RNA methylation-related long non-coding RNAs (IncRNAs) in GC are very limited in the literature. We aimed to investigate the prognostic potential of m$^6$A-related IncRNAs in predicting prognosis and monitoring immunotherapy efficacy in GC patients.

Methods: Transcriptome and clinical data were obtained from GC biopsies from Cancer Genome Atlas (TCGA). M$^6$A-related IncRNAs associated with GC were identified by constructing a co-expression network, and the gene pairs differentially expressed in GC were selected using univariate analysis. We constructed a risk model based on prognosis-related IncRNA pairs selected using the LASSO algorithm and quantified the best cutoff by comparing the area under the curve (AUC) for risk stratification. A risk model with the optimal discrimination between high- and low-risk GC patients was established. Its feasibility for overall survival prediction and discrimination of clinicopathological features, tumor-infiltrating immune cells, and biomarkers of immune checkpoint inhibitors between high- and low-risk groups were assessed.

Results: Finally, we identified 11 m$^6$A-related IncRNA pairs associated with GC prognosis based on transcriptome analysis of 375 GC specimens and 32 normal tissues. A risk model was constructed with an AUC of 0.8790. We stratified GC patients into high- and low-risk groups at a cutoff of 1.442. As expected, patients in the low-risk group had longer overall survival versus the high-risk group. Infiltration of cancer-associated fibroblasts, endothelial cells, macrophages, particularly M2 macrophages, and monocytes was more severe in high-risk patients than low-risk individuals, who exhibited high CD4$^+$ Th1 cell infiltration in GC. Altered expressions of immune-related genes were observed in both groups. PD-1 and LAG3 expressions were found higher in low-risk patients than high-risk patients. Immunoetherapy, either single or combined use of PD-1 or CTLA4 inhibitors, had better efficacy in low-risk patients than high-risk patients.

© The Author(s) 2022. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

*Correspondence: pengfeiyuan@haust.edu.cn; liudechun33@163.com
$^1$ Department of Gastrointestinal Surgery, The First Affiliated Hospital, and College of Clinical Medicine of Henan University of Science and Technology, No.24 Jinghua Road, Jianxi District, Luoyang 471003, China
Full list of author information is available at the end of the article
Conclusion: The new risk model based on a 11-m^6A-related IncRNA signature can serve as an independent predictor for GC prognosis prediction and may aid in the development of personalized immunotherapy strategies for patients.

Keywords: N^6-methyladenosine, Long non-coding RNA, Gastric cancer, Prognosis, Immunotherapy

Introduction
GC is the fifth most common malignancy worldwide, with a high incidence of new cases of 1 million each year, according to the 2018 statistics [1]. In China, GC is the second-largest malignancy regarding both morbidity and mortality, just following lung cancer [2]. Despite advances in diagnostics and treatment, a substantial number of patients with new lesions failing to be detected are often confirmed until a late stage, facing higher risks of metastasis and failure of anti-cancer therapy. For all the efforts that have been made for a better prognosis, the average 5-year survival rate of GC is still around 30%, while that of early-to-middle stage patients surprisingly reaches 60% [3, 4]. Even the promising immune checkpoint inhibitors (ICIs), which are expected to offer greater clinical benefits to patients with various cancers, including GC, reveal limited efficacy in advanced patients. Identification of sensitive biomarkers for early diagnosis and prognosis prediction is urgently needed.

Immune checkpoints may impede T cell activation by triggering several inhibitory signaling pathways, which is a key mechanism responsible for tumor cell escape from host immune recognition and T cell-mediated killing. ICIs, which block immunosuppressive signals and boost the activity of immune cells, seem to become a "game changer" for cancer treatment in the twenty-first century. PD-1/PD-L1 inhibitors are the most effective drugs to boost clinical response to immunotherapy [5, 6]. However, the global, multicenter, phase 2 KEYNOTE-059 study ascertained a fair response of advanced GC to pembrolizumab, which was only approved for use as a third-line treatment [7]. In the phase 3 ATTRACTION-2 study, nivolumab significantly increased the survival rate of progressive GC patients after ineffective chemotherapy [8]. The 2021 Chinese Society of Clinical Oncology (CSCO) included immunotherapy for the first-line/second-line treatment of GC [9]. These shreds of evidence support the efficacy of ICIs in GC treatment, but more new drugs are needed to offer more options for advanced patients.

N^6-methyladenosine (m^6A) refers to methylation in the N^6 position of adenosine. It frequently occurs in the RRACH sequence near the 3′ non-coding region, stop codon, and long internal exon [10]. This modification affects RNA fate in mammalian cells by dynamically and reversibly regulating the charge of RNA base, the secondary structure of RNA, and protein-RNA interaction to alter RNA transport, localization, translation, and degradation [11, 12]. Therefore, m^6A-associated cancer development in various cancer types, including GC, has been intensively studied [13, 14]. Current GC studies primarily focus on m^6A modification in protein-coding genes promoting prognosis [15]. But the effect of m^6A-associated non-coding RNAs on GC and their prognostic value, yet little explored, is important for immune monitoring and long-term remission in these patients. LncRNAs represent a type of transcript exceeding 200 nucleotides of length, accounting for about 90% of the human transcriptome [16]. They generally do not encode proteins yet regulate RNA expression at the epigenetic, transcriptional, or post-transcriptional level [17]. M^6A IncRNA modification is associated with a shift towards an immune-inflamed phenotype in cancers, characterized by immune cell infiltration into the tumor microenvironment (TME) [18, 19], suggesting that it may effectively determine tumor cell survival and efficacy of anti-cancer therapies. M^6A-related IncRNAs signatures have been shown to have pronounced correlations with the TME and expressions of critical immune checkpoints in hepatocellular carcinoma [20] and lung adenocarcinoma [21]. However, these models for prognosis prediction or assessment of immune cell infiltration and expressions of immune checkpoints in GC have not been reported elsewhere.

In this study, we aimed to develop a new risk model for various predictions for GC patients and constructed a new iteration algorithm for optimal gene-pairing strategies. Predictive performances of the risk model in low- and high-risk patients stratified by the optimal cutoff calculated based on AUCs were assessed. For the feasibility of this model, we evaluated whether it could discriminate differences in immune cell subpopulations between low- and high-risk groups. Correlation analyses were performed to determine whether there were relationships between the new risk model we constructed and known biomarkers for predicting the efficacy of immunosuppressive therapy. Overall, this study will provide fresh insights into the roles of m^6A-related IncRNAs in the prediction of GC prognosis and immunotherapy efficacy.

Methods
Transcriptome analysis for m^6A-related IncRNAs in GC
We integrated clinical and transcriptome (or RNA-seq) data from TCGA (https://gdc.cancer.gov/) in March 2021 for identifying m^6A-related IncRNAs differentially
expressed between GC and healthy controls. Patients were included if they fulfilled the following criteria: (1) they were histopathologically diagnosed; (2) tissue samples were obtained by surgery or tissue biopsy prior to other clinical treatments; and (3) clinical information as tissue ID, age, sex, grade, stage, and follow-up time was complete. Patients younger than 18 years or with incomplete clinical information were excluded, and patients not participating in any follow-up visits were also ruled out. Ensembl IDs from the pooled transcriptome data were converted to gene symbols. Survival time and status, age, gender, clinical stage of GC, and other clinical information were extracted and documented. We compiled a list of aberrantly expressed IncRNAs from the GC transcriptomes downloaded from Ensembl (http://asia.ensembl.org). m6A-related IncRNAs associated with GC were identified using co-expression network analysis in R software, and genes with a correlation coefficient > 0.4 and a P-value < 0.001 were selected. Interactions between m6A modifications and GC-associated IncRNAs were visualized. m6A-related IncRNAs differentially expressed between GC patients and healthy controls were screened with limma in R and genes at a false discovery rate (FDR) < 0.05 and log2 fold change (FC) filter = 1 were included.

**Construction of m6A-related IncRNA pairs in GC**
Differentially expressed m6A-related IncRNAs were paired by expression pattern ranks. Each IncRNA's expression level was converted to its rank within the same sample. Expressions of paired IncRNAs were ranked using a 0-or-1 matrix equation: \( C = \text{IncRNA}-A + \text{IncRNA}-B \). C is defined as 1 if the expression level of IncRNA A was higher than that of IncRNA B, otherwise C is defined as 0. After two cycles of expression ranking, IncRNA pairs with a stable expression order, whether \( C = 0 \) or \( 1 \), in 20-80% of all patient samples, were selected as stable m6A-related IncRNA pairs.

**Identification of m6A-related prognostic IncRNA pairs and construction of a prognostic risk model**
We integrated m6A-related IncRNA pairs with overall survival data from the TCGA cohort with limma. The combined gene expression and survival data were subjected to univariate Cox regression analysis to identify prognostic IncRNA pairs, and those with a \( P < 0.001 \) were regarded as gene candidates. These genes were tested in the 1000-times-repeated LASSO-Cox regression model, of which those with a frequency of over 100 times were included for Cox proportional hazard regression analysis to construct a multigene signature. ROC curves analysis was performed to obtain the highest (area under the curve) AUC value, which determined the optimal risk model for prediction. The average risk score of each patient was calculated using the optimal model (the highest AUC) established, and the best predictive cutoff for risk stratification was the point at which the sum of sensitivity and specificity was maximal in ROC curves. Patients were assigned to low- and high-risk groups according to the optimal risk score cutoff, and 1-, 2-, and 3-year AUC values of the risk model were calculated to validated prediction accuracy.

**Validation of the prognostic risk model**
We performed the Kaplan-Meier survival analysis to validate the accuracy of this prognostic model in discriminating the survival difference between low- and high-risk groups. Cox regression analysis for potential associations between clinicopathological features and the riskScore (the coefficient multiplied by the expression of each IncRNA pair) was carried out to evaluate the independence of the model. The Chi-square test was used to compare the AUCs for the difference in survival prediction between the model versus other clinicopathological biomarkers, and results were visualized in heatmaps. The Wilcoxon symbolic rank-sum test was used to examine the association between the riskScore and clinicopathological features.

**Tumor mutational burden (TMB) and somatic mutation analyses**
We assessed tumor mutations in the high- and low-risk groups with ggpubr in R. Kaplan-Meier survival analysis was performed for survival differences between high- and low-TMB GC specimens stratified by a surv-cutpoint determined by the survminer package in R. Somatic mutations in the high- versus low-risk groups were explored with maftools in R and visualized on oncoplots.

**Comparison of tumor-infiltrating immune cell subpopulations between risk groups**
We employed TIMER, XCELL, QUANTISEQ, MCP-COUNTER, EPIC, CIBERSORT-ABS, CIBERSORT algorithms for immune infiltration estimations to assess differences in immune cell subpopulations between low- and high-risk patients. The difference in immune cell landscape between the two risk groups was assessed using the Wilcoxon symbolic rank-sum test.

**Relationship between biomarkers for ICIs and the IncRNA pairs in the risk model**
We explored the relationship between the IncRNA pairs used in the prognostic model and the expression levels of known biomarkers for ICI treatment monitoring with ggpubr in R. We also assessed the performance of this model in predicting the efficacy of single or combined
use of PD1 and CTLA4 inhibitors in high- and low-risk groups, and the results were summarized in violin plots. The analyses were based on the cases in the TCGA cohort with clinical information as tissue ID, age, sex, grade, stage, and follow-up time, etc. Other information as clinical treatments (chemotherapy and/or immunotherapy, before or after surgery) were unavailable.

Statistical analysis
R software version 4.0.2 was utilized for all statistical analyses. Kaplan-Meier survival curves were plotted with the log-rank test. We employed the Chi-square test to compare differences in clinicopathological characteristics between the low- and high-risk groups. The Spearman rank correlation test was performed for correlation analysis. The significance level was set at $P < 0.05$.

Results
Identification of differentially expressed m\textsuperscript{6}A-related lncRNAs in GC
Initially, 489 m\textsuperscript{6}A-related lncRNAs were identified using co-expression network analysis, and a complete network of relationships between m\textsuperscript{6}A modifications and GC-associated lncRNAs was plotted (Fig. 1A). Next, 288 m\textsuperscript{6}A-related lncRNAs were found differentially expressed in GC, including 49 downregulated genes and 239 upregulated ones (Fig. 1B and C, and Supplementary Additional file 1).

Construction of the risk model based on m\textsuperscript{6}A-related prognostic lncRNA pairs
Based on 288 m\textsuperscript{6}A-related lncRNAs, 20,602 m\textsuperscript{6}A-related differential lncRNA pairs were primarily identified, and 11 pairs associated with patient survival were identified using the LASSO algorithm (Fig. 2A and B) and incorporated into a Cox proportional hazard model to construct a prognostic gene signature (Fig. 2C). The ROC curve analysis showed that the AUC of the new model for risk stratification was 0.804, with the best cutoff of 0.911 (Fig. 2D). Patients were divided into low- and high-risk groups according to the best cutoff. The 1-, 2-, and 3-year AUCs for overall survival prediction in GC were 0.804, 0.778, and 0.791 (Fig. 2E), compared to the AUCs for the performances of age, gender, cancer grading, and clinical staging in survival prediction of 0.587, 0.524, 0.557, and 0.597, respectively, suggesting a superior prediction of this model (Fig. 2F).

The risk model serves as an independent prognostic indicator for GC
In the TCGA cohort, 438 GC cases who had complete prognostic information were included in our analysis (Supplementary Additional file 2). All tissue samples were collected during surgical resections or biopsy procedures. Except for 27 cases with missing information, we had 56, 130, 181, and 44 patients with stage I-IV GC, respectively, according to the 7th edition of the AJCC. The median follow-up was 595 days (range, 7-2197 days). Based on the best cutoff, 178 patients were classified into the high-risk group and 172 into the low-risk group. The average riskScore and survival outcome of each group were summarized in Fig. 3A and B. The Kaplan-Meier survival analysis showed that the overall survival of low-risk patients was significantly extended versus high-risk patients ($P < 0.001$) (Fig. 3C). Univariate and multivariate Cox regression of risk ratio revealed that the riskScore could act as an independent risk indicator for overall survival prediction (univariate
Cox regression: HR 1.434, 95%CI 1.332-1.542, P < 0.001; multivariate Cox regression: HR 1.472, 95%CI 1.360-1.594, P < 0.001 (Fig. 3D and E).

**TMB and somatic mutation analyses in the high-versus low-risk groups**

The TMB analysis showed more frequent mutations in the low-risk group versus the high-risk group (P = 0.0095) (Fig. 4A). Better survival was observed in high-TMB patients (n = 303) versus low-TMB patients (n = 39), classified upon their TMB estimates, which was consistent with better overall survival in low-risk patients (Fig. 4B). In somatic mutation analysis, a higher somatic mutation rate of 91.01% was found in the low risk group compared to 84.31% in the high risk group, which were most common in TTN (51% vs. 42%), TP53 (42% vs. 39%), and MUC16 genes (34% vs. 24%) (Fig. 4C and D).

**The m6A-related lncRNAs-based risk model predicts immune cell landscape associated with GC risk**

We assessed the potential relationships of immune cell subpopulations with GC risk to explore whether the m6A-related prognostic lncRNA pairs used in the risk model were involved in activities in the tumor immune microenvironment (TIME). A significant correlation was observed between alterations in the immune cell landscape and increased GC risk (Fig. 5). The differential analysis revealed markedly increased infiltration of cancer-associated fibroblasts, endothelial cells, macrophages, particularly M2 macrophages, and monocytes in high-risk patients, and high CD4+ Th1 cell infiltration, for anti-tumor immune response, in low-risk patients (Fig. 6A to F).

**Differences in immune-related genes between low-versus high-risk GC patients**

As immunotherapy is the common treatment for GC, whether the m6A-related lncRNAs used in the model were associated with biomarkers for ICI treatment monitoring was examined. We found higher expressions of immune-related genes as VEGFC, VCAN, and APOLD1 in the high-risk group and increased PDXY expression in low-risk patients (Fig. 7A to D). We also analyzed the differential expressions of frequently detected immune checkpoint genes as PD-1(PDCD1), PD-L1(CD274), CTLA4, TIM3(HAVCR2), LAG3, and TIGIT between the two risk groups, of which PD-1 and LAG3 expressions...
were significantly upregulated in the low- versus high-risk groups (Fig. 7E to J). The analysis of immunotherapy efficacy showed that either single use of anti-PD1 or CTLA therapy or their combination had better efficacy in low-risk patients than those achieved in high-risk patients (Fig. 7K to N).

**Discussion**

Although the roles of m6A lncRNA modification in facilitating tumor occurrence and development have been reported in several studies, the current knowledge concerning its role in GC development and progression remains limited. Alterations in malignant behaviors of tumor cells by m6A regulators have been reported to be an important mechanism responsible for tumor progression [22]. However, whether the mechanism to maintain tumor cell growth and survival is lncRNA-dependent remains unknown because of limited data on m6A lncRNA modification in particular cancer types, including GC. In the current study, a prognostic risk model was constructed based on m6A-related lncRNA pairs selected using the LASSO algorithm. The risk scoring model (the median riskScore) for risk stratification was confirmed based on ROC curves. We found m6A-related prognostic lncRNA pairs used in the risk model were associated with not only patient survival but immune cell infiltration and alterations in immune-related genes, contributing to a better knowledge of lncRNA biomarkers for GC prognosis and immunotherapies.

In this work, we integrated transcriptome and clinical data of GC patients from TCGA, identified m6A-related prognostic lncRNAs associated with GC prognosis, and constructed lncRNA pairs using a 0-or-1 matrix. Finally, a risk model for GC risk was developed based on these prognostic lncRNA pairs using a 1000-times-repeated LASSO regression model proposed by Sveen et al. [23]. Prognostic gene pairs were selected upon their frequency rather than intersections in the 1000 times of random stimulation for a more accurate prediction. Here are the improvements in modeling we made: the best cutoff for risk prediction and an optimal risk model selected using the highest AUC for more accurate prognostic prediction. All these added to the credibility of our results. Our risk model has been shown to effectively discriminate high-risk patients who may develop GC, as well as specific clinicopathological features and tumor-infiltrating immune cell landscape. Besides, we utilized a 0-or-1 matrix upon expression order instead of expression level to identify differentially expressed lncRNAs more efficiently, either upregulated or downregulated. Moreover, high TMB has been shown to have associations with good prognosis and enable GC efficacy prediction, thus can be used as a biomarker [24]. The somatic mutation analysis highlighted the great majority of mutations in
TTN and MUC16 genes in both the high- and low-risk groups, which have been proven to show significant associations with GC prognosis and offer TMB prediction or efficacy prediction in immunotherapy [25]. In this study, we also found higher TMB in the low-risk group, suggesting a relationship of high TMB with favorable survival.

In the TIME, m6A modification may change the patterns of tumor-infiltrating immune cells being recruited remotely, suppressing response to immunotherapy and ultimately driving tumor cell proliferation and survival and tumor progression in patients. The effect of m6A modification on immune cells in the TIME is critical for immune escape and patient outcome [26]. The efficacy of immunotherapy, particularly PD-1/PD-L1 inhibitors, in various cancers has been widely explored and discussed. A robust anticancer immune response can be restored via blocking immune checkpoint receptors and their ligands, thus increasing immune-mediated tumor clearance in the TIME [19, 26, 27]. For far too long, little has been written on m6A modification and tumor-infiltrating immune cell landscape in cancers, even though it is known that the efficacy of immunotherapy and patient outcome are closely related to immune cell infiltration [28]. The latest study ascertained that reduced m6A modification by knocking out methyltransferase genes, Mettl3 and Mettl14, enhanced response to
PD-1 inhibitors in murine colorectal carcinoma cell line CT26 [29]. This finding provides a clue that an m6A-related signature may be important to shape the immune cell landscape in high-risk populations and predict response to immunotherapy, which are crucial for enhancing the success rate of immunotherapy. We compared the difference in immune cell subpopulations between low- and high-risk patients stratified by the risk score cutoff and assessed the association of m6A-related lncRNA pairs selected for the risk model with immune cell infiltration using TIMER [30], XCELL [31], QUANTISEQ [32], MCPCOUNTER, EPIC, CIBERSORT [33], CIBERSORT-ABS algorithms [34]. These gene pairs showed tight associations with high CD4+ T cell, macrophage, monocyte, and myeloid dendritic cell infiltration. Cancer-associated fibroblasts, endothelial cells, hematopoietic cells, resting memory CD4+ T cells in patients at high risk of GC were significantly abundant versus low-risk cases. There were more macrophages, macrophage-monocyte lineage cells, monocytes, neutrophils, and CD4+ Th1 cells infiltrated in tumor tissues of low-risk patients. These findings suggest that m6A lncRNA modification may be involved in the inhibition of the anti-cancer immune response in high-risk patients. Our findings were in line with the studies of m6A-related lncRNA signature in bladder cancer [35], which based on 9 lncRNAs. Compared with that study, our risk model was constructed based on 11 lncRNA pairs, which may reduce the batch corrections and increase the accuracy of the analyses.

Recent reports have shown that only a small group of cancer patients can benefit from ICIs [36], which calls for new biomarkers for ICI response prediction or even related adverse event prediction. In this study, we identified three immune-related genes, VEGFC, VCAN, and TNFSF, overexpressed in tumor tissues of high-risk patients and PDXY and APOLD1 upregulated in the low-risk group. This model is apt at discriminating aberrant immune checkpoint genes in different risk groups. Among the immune checkpoint genes, PD-1, PD-L1, CTLA4, TIM3, LAG3, and TIGIT frequently detected in most ICI research [36, 37], we found PD-1 and LAG3 expressions were upregulated in the high-risk group versus the low-risk group. We also found that either single use of anti-PD1 or CTLA therapy or their combination had better efficacy in low-risk patients than those achieved in high-risk patients. That means low-risk patients can also benefit from ICIs, whatever the specific agents or combination regimens.
The findings above suggest that this risk model is an excellent option for monitoring immunotherapeutic efficacy.

**Conclusion**

In summary, we developed a risk model based on m6A-related prognostic IncRNA pairs for GC risk using the optimal modeling algorithms. It effectively shapes the tumor-infiltrating immune cell landscape and predicts the efficacy of immunotherapy in low- and high-risk patients, which can be used as an accurate and independent predictor for GC risk. The 11-m6A-related IncRNA signature used in the model is worthy of further exploration to offer therapeutic targets for better immunotherapy. However, more information of the TCGA cohort, such as medication schedules, surgical records, and pathological reports, are unavailable but essential for insightful analysis, which is expected in our future publication in a timely manner. Large-sample, multicentre studies of assessment of m6A-related IncRNA-based risk model in GC prognosis prediction are needed.

**Abbreviations**

AUC: Area under the curve; GC: Gastric cancer; IncRNAs: Long noncoding RNAs; m6A: N6-methyladenosine; TCGA: The Cancer Genome Atlas; TIME: Tumor immune microenvironment; VIRMA: Vir-like m6A methyltransferase association; ALKBH5: Alkylation repair homolog protein 5.

**Supplementary Information**

The online version contains supplementary material available at https://doi.org/10.1186/s12885-021-09062-2.

- Additional file 1.
- Additional file 2.

**Acknowledgements**

Not applicable.

**Authors’ contributions**

LL and LN carried out data analysis. LL and LD drafted the manuscript; YP participated in study design and data collection. All authors read and approved the final manuscript.

**Funding**

This study was supported by the Henan Provincial Programs for Science and Technology Development (No.201504021).

**Availability of data and materials**

All data generated or analyzed during this study are included in this published article (and its supplementary information files). The raw-clinical and transcriptome (or RNA-seq) data used in this study were all available from the TCGA database (https://portal.gdc.cancer.gov/repository?facetTab=files&filter=7%22pp%22%3A%22and%22%2C%22content%22%3A%3B%228%22op%22%3A%22in%22%2C%22content%22%3A%22%22%2%22field%22%3A%22cases.prima...
Fig. 7 Differences in immune-related and immune checkpoint genes in low- versus high-risk GC patients. A to C VEGFC, VCAN, and APOLD1 gene expressions are upregulated in the high-risk group. D PDXK, F PD-1, and G LAG3 was highly expressed in the low-risk group, whereas E HAVCR2 (TIM3), H CTLA4, I TIGIT, and J PD-L1 show no significant differences in expression levels between low- versus high-risk groups. K The efficacy of the common ICI treatments, CTLA4 and PD1 inhibitors, in the high- and low-risk groups using immunoscores. Low-risk patients receiving L single PD-1 inhibitors or M CTLA4 inhibitors or N their combination have better responses than high-risk patients. *P < 0.05, **P < 0.01, ***P < 0.001

**Declarations**

**Ethics approval and consent to participate**
This article does not contain any studies with human participants or animals performed by any of the authors, therefore no ethic approval or consent is required. No administrative permission and/or licenses is acquired by this study to access the original data used in this research.

**Consent for publication**
Not applicable.

**Competing interests**
The authors have declared that no competing interest exists.
Author details
1 Department of Gastrointestinal Surgery, The First Affiliated Hospital, and College of Clinical Medicine of Henan University of Science and Technology, No.24 Jinghuang Road, Jiaxi District, Luoyang 471003, China. 2 Department of Ultrasoundography, The Sixth People’s Hospital of Luoyang, Luoyang 471003, China.

Received: 30 April 2021 Accepted: 22 November 2021
Published online: 05 April 2022

References
1. Feng RM, Zong YN, Cao SM, Xu RH. Current cancer situation in China: good or bad news from the 2018 Global Cancer Statistics? Cancer Commun. 2019;39(1):22.
2. Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66(2):115–32.
3. Smyth EC, Nilsson M, Grabsch HI, van Grieken NC, Lordick F. Gastric cancer. Lancet. 2020;396(10251):635–48.
4. Karimi P, Islami F, Anandasabapathy S, Freedman ND, Kamangar F. Gastric cancer: descriptive epidemiology, risk factors, screening, and prevention. Cancer Epidemiol Biomarkers Prev. 2014;23(5):700–13.
5. Tang W, Chen Y, Chen S, Sun B, Gu H, Kang M. Programmed death-1 (PD-1) polymorphism is associated with gastric cardia adenocarcinoma. Int J Clin Exp Med. 2015;8(5):8086–93.
6. Li J, Chen L, Xiong Y, Zheng X, Xie Q, Zhou Q, et al. Knockdown of PD-L1 in human gastric cancer cells inhibits tumor progression and improves the cytotoxic sensitivity to CIK therapy. Cell Physiol Biochem. 2017;41(3):907–20.
7. Bang YJ, Kang YK, Catenacci DV, Muro K, Fuchs CS, Geva R, et al. Pembrolizumab alone or in combination with chemotherapy as first-line therapy for patients with advanced gastric or gastroesophageal junction adenocarcinoma: results from the phase II nonrandomized KEYNOTE-059 study. Gastric Cancer. 2019;22(4):828–37.
8. Kang YK, Boku N, Satoh T, Ryu MH, Chao Y, Kato K, et al. Nivolumab in patients with advanced gastric or gastroesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;390(10111):2461–71.
9. Wang FH, Shen L, Li L, Zhou ZJ, Liang H, Zhang XT, et al. The Chinese Society of Oncological Science (CSCO): clinical guidelines for the diagnosis and treatment of gastric cancer. Cancer Commun. 2019;39(1):10.
10. He L, Li H, Wu A, Peng Y, Shu G, Yin G. Functions of N6-methyladenosine and its role in cancer. Mol Cancer. 2019;18(1):176.
11. Reichel M, Köster T, Staiger D. Marking RNA: m6A writers, readers, and erasers. Nat. Rev. Mol. Cell Biol. 2017;18(1):75–88.
12. Zaccara S, Ries RJ, Jaffrey SR. Reading, writing and erasing mRNA methylation in Arabidopsis. J Mol Cell Biol. 2019;11(10):899–910.
13. Zaccara S, Ries RJ, Jaffrey SR. Reading and erasing m6A methylation. Nat Rev Mol Cell Biol. 2019;20(10):628–41.
14. Yue B, Song C, Yang L, Cui R, Cheng X, Zhang Z, et al. METTL3-mediated N6-methyladenosine modification is critical for epithelial-mesenchymal transition and metastasis of gastric cancer. Mol Cancer. 2019;18(1):142.
15. Jang L, Chen T, Xiong L, Xu JH, Gong AY, Dai B, et al. Knockdown of m6A methyltransferase METTL3 in gastric cancer cells results in suppression of cell proliferation. Oncol Lett. 2020;20(5):2919–25.
16. Zhang B, Wu Q, Li B, Wang D, Wang L, Zhou YL. m6A regulator-mediated methylation modification patterns and tumor microenvironment infiltration characterization in gastric cancer. Mol Cancer. 2020;19(1):53.
17. Jathar S, Kumar V, Srivastava J, Tripathi V. Technological developments in IncRNA biology. Adv Exp Med Biol. 2017;1008:283–323.
18. Charles Richard JL, Eichhorn PJ. Platforms for investigating IncRNA functions in Ultrasil. Nat Rev Genet. 2018;23(6):493–506.
19. Wang M, Li Z, Peng Y, Fang J, Fang T, Wu J, et al. Identification of immune cells and mRNA associated with prognosis of gastric cancer. BMC Cancer. 2020;20(1):26.
20. Refolo MG, Lotersztajn C, Messa C, Caruso MG, D’Alessandro R. Integrated immune gene expression signature and molecular classification in gastric cancer: new insights. J Leukoc Biol. 2020;108(2):633–46.
21. Xu F, Huang X, Li Y, Chen Y, Lin M. m6A-related IncRNAs are potential biomarkers for predicting prognoses and immune responses in patients with LUAD. Mo Ther Nucleic Acids. 2021;24:780–91.
22. Dai D, Wang H, Zhu L, Jin H, Wang X. N6-methyladenosine links RNA metabolism to cancer progression. Cell Death Dis. 2018;9(2):124.
23. Sveen A, Ågesen TH, Nesbakken A, Meling GI, Rognum TO, Liestøl K, et al. ColoGuidePro: a prognostic 7-gene expression signature for stage III colorectal cancer patients. Clin Cancer Res. 2012;18(21):6001–10.
24. Petrillo A, Smyth EC. Biomarkers for precise treatment in gastric cancer. Visc Med. 2020;36(5):364–72.
25. Yang Y, Zhang J, Chen Y, Xu R, Zhao Q, Guo W. MUC4, MUC16, and TTN genes mutation correlated with prognosis, and predicted tumor mutation burden and immunotherapy efficacy in gastric cancer and pan-cancer. Clin Transl Med. 2020;10(4):e153.
26. Quail DF, Joyce JA. Microenvironmental regulation of tumor progression and metastasis. Nat Med. 2013;19(11):1423–37.
27. Li Y, Wang C, Xu M, Kong C, Qu A, Zhang M, et al. Preoperative NLR for predicting survival rate after radical resection combined with adjuvant immunotherapy with CIK and postoperative chemotherapy in gastric cancer. J Cancer Res Clin Oncol. 2017;143(5):861–71.
28. Radjans A. Prognostic and predictive significance of immune cells infiltrating cutaneous melanoma. Pigment Cell Melanoma Res. 2015;28(5):490–500.
29. Dienstmann R, Villacampa G, Sveen A, Mason MJ, Niedzwiecki D, Nesbakken A, et al. Relative contribution of clinicopathological variables, genomic markers, transcriptomic subtyping and microenvironment features for outcome prediction in stage III/IV colorectal cancer. Ann Oncol. 2019;30(10):1622–9.
30. Li Z, Fan J, Wang B, Traugh J, Chen Q, Liu JS, et al. TIMER: a web server for comprehensive analysis of tumor-infiltrating immune cells. Cancer Res. 2017;77(21):e108–10.
31. Aran D. Cell-type enrichment analysis of bulk transcriptomes using xCell. Methods Mol Biol. 2020;2021:263–76.
32. Plattner C, Finotello F, Rieder D. Deconvoluting tumor-infiltrating immune cells from RNA-seq data using quanTIseq. Methods Enzymol. 2020;636:261–85.
33. Chen B, Khodadoust MS, Liu CL, Newman AM, Alizadeh AA. Profiling tumor infiltrating immune cells with CIBERSORT. Methods Mol Biol. 2018;1711:245–59.
34. Racle J, de Jonge K, Baumgaertner P, Speiser DE, Gfeller D. Simultaneous identification of immune cells and mRNA associated with prognosis of gastric cancer. BMC Cancer. 2018;18(11):243–59.
35. Li Z, Yi Y, Zhong W, Huang P. m6A-related lncRNA to develop prognostic signatures and predict the immune landscape in bladder cancer. J Oncol. 2021;2021:7488188.
36. de Miguel M, Calvo E. Clinical challenges of immune checkpoint inhibitors: recent progress and potential biomarkers. Exp Mol Med. 2021;53(12):e26476.
37. de Miguel M, Calvo E. Clinical challenges of immune checkpoint inhibitors: recent progress and potential biomarkers. Exp Mol Med. 2020;52(12):1–11.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.